REFERENCES
- Rinaldi GM. Zygomycosis. Infect Dis Clin North Am 1989; 3: 19–41.
- Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001; 44(7-8): 253-60.
- Petrikkos G, Skiada A, Sambatakou H, Toskas A, Vaiopou-los G, Giannopoulou M, et al. Zygomycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 12: 753–6.
- Sugar AM. Zygomycosis. Clin Infect Dis 1992; 14(Suppl 1): 126–9.
- Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, etal. Zygomycosis in patients with haematological malignan-cies: a retrospective clinical study of 37 cases. Br J Haem 1997; 99: 331–6.
- Kontoyiannis DP, Wessel VC, Bodey GP, Rolston Ky. Zy-gomycosis in the 1990s in a tertiary-care cancer center. Clin In-fect Dis 2000; 30: 851–6.
- Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al. Zygomycosis in hematologic patients. Haema-tologica. 2004; 89 (2): 207–14.
- De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal dis-ease from the European Organization for Research and treat-ment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases My-coses Study Group (EORTC/MSG) Consensus Group. Clin In-fect Dis 2008; 46 (12): 1813–21.
- Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C etal. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and treat-ment of Cancer Consensus Criteria. Clin Infect Dis 2008; 47: 674–83.
- StataCorp. 2003. Stata Statistical Software: Release 8.1. College Station, TX: Stata Corporation.
- Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45 (4): 321–46.
- Rickerts V, Bohme A, Just-Nubling G. Risk factor for in-vasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45(Suppl 1):27–30.
- Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (5): 634–53.
- Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191 (8): 1350–60.
- Morrison VA, McGlave PB. Zygomycosis in the BMT pop-ulation. Bone Marrow Transpl 1993; 11: 383–8.
- Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, et al. Zygomycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000; 85: 1068–71.
- Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epi-demiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–17.
- Gupta T, Sachdev N, Kaur J, Dey P, Gupta V, Gupta A. Endogenous mycotic endophthalmitis in an immunocompetent patient. Int Ophthalmol 2008.
- Tehmeena W, Hussain W, Zargar HR, Sheikh AR, Iqbal S. Primary cutaneous mucormycosis in an immunocompetent host. Mycopathologia 2007; 164 (4): 197–9.
- Jain D, Kumar Y, Vasishta RK, Rajesh L, Pattari SK, Chakrabarti A. Zygomycotic necrotizing fasciitis in immunocom-petent patients: a series of 18 cases. Mod Pathol 2006; 19 (9): 1221–6.
- Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45–52.
- Chamilos G, Lewis RE, Kontoyiannis DP. Delaying am-photericin B-based frontline therapy significantly increases mor-tality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47 (4): 503–9.
- Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravu-conazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimi-crobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032–7.
- Greenberg RN, Mullane K, Van Bunk JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as savage therapy for zy-gomicosis. Antimicrob Chemother 2006; 50 (1): 126–33.